Mon. 20 May 2024, 8:14am ET
Benzinga
Biotech, News, FDA, General
Management believes that the meeting was highly informative and views the FDA's feedback as very constructive. Based on the feedback received as well as the Meeting Minutes expected in June, ENDRA will update its pivotal clinical study protocol and statistical plan for submission to the FDA as a next step prior to initiating the study.